ReviewRespiratory research2019
Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective.
Review in Respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- How to Enhance the Diagnosis of Early Stages of Chronic Obstructive Pulmonary Disease (COPD)? The Role of Mobile Spirometry in COPD Screening and Diagnosis-A Systematic Review.Advances in respiratory medicine · 2024Pooled it
- Patient outcomes following GPs' educations about COPD: a cluster randomized controlled trial.NPJ primary care respiratory medicine · 2020Trial
- The contributions of active and passive smoking to COPD-related mortality and DALYs in the context of COVID-19: Global Burden 2019-2021.Tobacco induced diseases · 2026Article
- Machine learning for detection of diffusion abnormalities-related respiratory changes among normal, overweight, and obese individuals based on BMI and pulmonary ventilation parameters: an observational study.BMC medical informatics and decision making · 2025Observational
- Risk of All-Cause Mortality in Mild Chronic Obstructive Pulmonary Disease: Evidence From the NHANES III and 2007-2012.International journal of chronic obstructive pulmonary disease · 2025Article
- DElaying Disease Progression In COPD with Early Initiation of Dual Bronchodilator or Triple Inhaled PharmacoTherapy (DEPICT): A Predictive Modelling Approach.Advances in therapy · 2023Article
- Efficacy and safety of once-daily single-inhaler triple therapy for mild-to-moderate chronic obstructive pulmonary disease: a study protocol for a randomised and interventional study.BMJ open respiratory research · 2023Article
- Most patients with COPD are unaware of their health threats and are not diagnosed: a national-level study using pulmonary function test.Scientific reports · 2023Article
- Treatment Patterns, Socioeconomic Status and Clinical Burden in Mild COPD: A Swedish Real-World, Retrospective Cohort Study, the ARCTIC Study.International journal of chronic obstructive pulmonary disease · 2022Article
- COPD - do the right thing.BMC family practice · 2021Review
- Diagnosis and Treatment of Early Chronic Obstructive Lung Disease (COPD).Journal of clinical medicine · 2020Review
- The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline.International journal of chronic obstructive pulmonary disease · 2020Article
- Active screening for COPD among hospitalized smokers - a feasibility study.Therapeutic advances in chronic disease · 2020Article
- Early COPD: current evidence for diagnosis and management.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
There is increasing focus on understanding the nature of chronic obstructive pulmonary disease (COPD) during the earlier stages. Mild COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 1 or the now-withdrawn GOLD stage 0) represents an early stage of COPD that may progress to more severe disease. This review summarises the disease burden of patients with mild COPD and discusses the evidence for treatment intervention in this subgroup.Overall, patients with mild COPD suffer a substantial disease burden that includes persistent or potentially debilitating symptoms, increased risk of exacerbations, increased healthcare utilisation, reduced exercise tolerance and physical activity, and a higher rate of lung function decline versus controls. However, the evidence for treatment efficacy in these patients is limited due to their frequent exclusion from clinical trials. Careful assessment of disease burden and the rate of disease progression in individual patients, rather than a reliance on spirometry data, may identify patients who could benefit from earlier treatment intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.